Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol.

[1]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[2]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[3]  W. Abraham,et al.  Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. , 1998, Journal of the American College of Cardiology.

[4]  A. Stäblein,et al.  Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. , 1997, Journal of the American College of Cardiology.

[5]  W. Abraham,et al.  Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. , 1996, Circulation.

[6]  J. Hare,et al.  Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension. , 1996, Journal of the American College of Cardiology.

[7]  M. Bristow,et al.  Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. , 1996, Circulation.

[8]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[9]  R. Cody,et al.  Short-term use of intravenous milrinone for heart failure. , 1995, American Journal of Cardiology.

[10]  L. Wilkins.  A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.

[11]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[12]  D. Gibson,et al.  Effects of intravenous milrinone on left ventricular function in ischemic and idiopathic dilated cardiomyopathy. , 1993, The American journal of cardiology.

[13]  H. Nawrath,et al.  Pharmacology of bipyridine phosphodiesterase III inhibitors. , 1991, European journal of anaesthesiology. Supplement.

[14]  W. Colucci.  Cardiovascular effects of milrinone. , 1991, American heart journal.

[15]  P. Merlet,et al.  Physiologic Assessment of Milrinone Therapy in Severe Heart Failure Patients , 1991, Journal of Cardiovascular Pharmacology.

[16]  A. Kux,et al.  Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure. , 1991, American heart journal.

[17]  R. Ogilvie,et al.  A Canadian multicentre study of a 48 h infusion of milrinone in patients with severe heart failure. , 1991, The Canadian journal of cardiology.

[18]  K Caidahl,et al.  Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. , 1989, Circulation.

[19]  P. Ludmer,et al.  Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition. , 1988, The Journal of clinical investigation.

[20]  D. Salem,et al.  Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1987, The American journal of cardiology.

[21]  C. Liang,et al.  Hemodynamic and regional blood flow response to milrinone in patients with severe congestive heart failure: a dose-ranging study. , 1987, American heart journal.

[22]  D. Faxon,et al.  Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. , 1987, The American journal of cardiology.

[23]  D. Baim,et al.  Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study. , 1987, Journal of the American College of Cardiology.

[24]  D. Baim,et al.  Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure. , 1985, Circulation.

[25]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[26]  C. Leier,et al.  Drugs five years later. Dobutamine. , 1983, Annals of internal medicine.

[27]  R. Magorien,et al.  The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy. , 1983, American heart journal.

[28]  E. Varnauskas,et al.  Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1975, British heart journal.